Company Overview
Snapshot
Founded in December 2024 by Marvin Collin, Rami Cohen, and Raphael Nir, Ascento-CDA operates with 1–10 employees. The company has raised $350,000 across one funding round. In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline, highlighting its scientific validation efforts.
Business overview
Ascento-CDA is a healthcare analytics company developing a scalable platform for the early detection of dementia and diabetes. Its proprietary analytic engine integrates immunology data, retinal imaging signals, and cognitive assessments to identify early biologic activity before symptoms manifest. The platform aims to reduce lifetime medical costs for insurers and payers through upstream intervention, while enabling new revenue streams for health providers via earlier diagnostics and pre-clinical care programs. Operating in the Health Tech & Life Sciences sector, specifically Digital Healthcare and Medical Decision Support, Ascento-CDA leverages artificial intelligence and machine learning to serve patients, insurance companies, and providers.
Strategic signal
In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline, utilizing inflammatory, immunologic, and cognitive mapping. This publication signals significant progress in validating their core technology and provides a strong scientific foundation for their approach to early disease detection, which is crucial for investor confidence and market adoption in the health tech sector.
Log in to access full profile ›Company Intelligence Q&A
- When was Ascento-CDA founded and by whom?
- Ascento-CDA was founded in December 2024 by Marvin Collin, Rami Cohen, and Raphael Nir.
- What is Ascento-CDA's primary focus?
- Ascento-CDA focuses on the early detection of dementia and diabetes by identifying biologic activity years before symptoms appear, using a proprietary analytic engine that integrates immunology data, retinal imaging, and cognitive assessments.
- What was a key scientific milestone for Ascento-CDA?
- In October 2025, Ascento-CDA published research on the early identification of disease promoters of cognitive decline using Inflammatory, Immunologic, and Cognitive Mapping (IICM™).
- How much capital has Ascento-CDA raised to date?
- Ascento-CDA has raised a total of $350,000 across one funding round.
- What markets does Ascento-CDA target?
- Ascento-CDA primarily targets the North American geomarket, serving patients, insurance companies, and providers within the healthcare sector.